
	Where results make sense

Topic: Meropenem

Related Topics

Vancomycin

Linezolid

Quinolones

Tetracycline

Penicillin

In the News (Sat 4 Jul 09)

Northern Trust

Marvin Harrison

Peter Chernin

Gary Locke

Match Play

Penelope Cruz

Mickey Rourke

AR Rahman

Danny Boyle

Hugh Jackman

	CIPLADOC - Cipla Therapeutic Index
		Meropenem has significant stability to hydrolysis by beta-lactamases of most categories, both penicillinases and cephalosporinases produced by gram-positive and gram-negative bacteria, with the exception of metallo beta-lactamases.
		Meropenem should be given as intravenous infusion over approximately 15 to 30 minutes or as an intravenous bolus injection (5 to 20 mL) over approximately 3-5 minutes.
		Meropenem is contraindicated in patients with known hypersensitivity to any component of this product or to other drugs in the same class or in patients who have demonstrated anaphylactic reactions to (beta)-lactams.
	www.cipladoc.com /therapeutic/admin.php?mode=prod&action=disp&id=389 (921 words)

	meropenem (Site not responding. Last check: 2007-10-15)
		A multicenter study of meropenem vs cefotaxime in the therapy of pediatric meningitis.
		The pharmacokinetics of meropenem in infants and children: A population analysis.
		Meropenem is primarily eliminated unchanged in the urine.
	pedsccm.wustl.edu /All-Net/english/pharmpage/antibx/Meropenem.html (1443 words)

	A New Carbapenem for Severe Infection
		Meropenem is a semisynthetic parenteral carbapenem with a broad spectrum of activity.
		Meropenem (40 mg/kg q8h) was administered intravenously by bolus injection or by infusion.
		Meropenem 3 g/day was found to be at least as effective as ceftazidime plus amikacin (6 g/day plus 15 mg/kg/day) in patients with severe nosocomial respiratory tract infections; clinical response rates of 81% vs. 72% and bacteriological eradication rates of 71% vs. 76% were reported.
	www.uspharmacist.com /oldformat.asp?url=newlook/files/Drug/ACF2EE6.cfm&pub_id=8&article_id=28 (2190 words)

	Indian Pediatrics - Editorial
		Meropenem is primarily excreted by the kidney with about half to three-fourths of dose excreted unchanged in the urine and a further one-fourth excreted as a microbiologically inactive open β-lactam metabolite(3,4).
		Meropenem appears to be promising in the treatment of hospitalized infants and children with serious infections because of its broad spectrum of antibacterial activity.
		Meropenem monotherapy was as effective as imipenem/cilastatin in 4 comparative trials in terms of satisfactory clinical and bacteriological responses in intensive care settings(29).
	www.indianpediatrics.net /may2005/may-443-450.htm (3094 words)

	AstraZeneca Clinical Trials
		Furthermore, 40% of meropenem patients were greater than 75 years of age, compared to 28% of imipenem/cilastatin patients, and more patients in the meropenem group had reduced baseline creatinine clearance values (<60 ml/min) compared to the imipenem/cilastatin group (55% versus 43%).
		The higher plasma concentration-time profiles noted in the present trial may be related to the demographic characteristics of the patients (age range of the 5 volunteers in the published trial was 20 to 39 years, compared to an age range of 45 to 68 years for the 5 patients in the present trial).
		Trial treatment (meropenem vs imipenem/cilastatin) and the presence of underlying chronic pulmonary disease (chronic bronchitis, bronchiectasis, or emphysema) were not significant predictors for serious adverse events as a whole, for deaths, or for recurrent pneumonia events.
	www.astrazenecaclinicaltrials.com /ncm.aspx?type=Article¶m=514137 (3622 words)

	Meropenem - Wikipedia, the free encyclopedia
		Meropenem is an ultra-broad spectrum injectable antibiotic used to treat a wide variety of infections, including meningitis and pneumonia.
		Unlike imipenem, it is stable to renal dehydrogenase and can therefore be given without cilastatin.
		Meropenem can be used interchangeably and is stable against kidney dihydropeptidase, therefore cilastin is not needed.
	en.wikipedia.org /wiki/Meropenem (123 words)

	Notice: Request for Public Comment on a Written Request Issued by the ..........
		Meropenem Written Request Dear Contact: To obtain needed pediatric information on the use of meropenem, the Food and Drug Administration (FDA) is hereby making a formal Written Request, pursuant to section 505A of the Federal Food, Drug, and Cosmetic Act that you submit information from studies in pediatric patients described below.
		Indication to be studied: Meropenem for the treatment of complicated intra-abdominal infections in preterm and term newborn and infant patients younger than 91 days of age.
		Meropenem pharmacokinetics in pre-term and full-term neonates [Abstract 686].
	www.pharmcast.com /FederalRegistrar/Yr2005/Jan2005/011705/Meropenem012105.htm (3405 words)

	Data Sheet
		Meropenem is a carbapenem antibiotic for parenteral use, that is stable to human dehydropeptidase-I (DHP-I).
		The elimination half-life for meropenem was increased to approximately 1.75 hours in 3-5 month old infants The concentrations of meropenem increase with increasing dose over the dose range of 10 to 40 mg/kg.
		Probenecid competes with meropenem for active tubular secretion and thus inhibits the renal excretion of meropenem with the effect of increasing the elimination half-life and plasma concentration of meropenem.
	www.medsafe.govt.nz /Profs/datasheet/m/MerremIVinj.htm (2226 words)

	MedicineOnline.com Drug Information: Meropenem Injection (Site not responding. Last check: 2007-10-15)
		The drug will be either injected into a large muscle (such as your buttock or hip) or added to an intravenous fluid that will drip through a needle or catheter placed in your vein for at least 15 minutes or more, one to three times a day.
		Meropenem eliminates bacteria that cause many kinds of infections, including pneumonia and urinary tract, skin, bone, and stomach infections.
		If you are receiving meropenem in your vein or under your skin, you need to know the symptoms of a catheter-related infection (an infection where the needle enters your vein or skin).
	www.medicineonline.com /druginfo/info1/Meropenem_Injection (702 words)

	Merrem I.V. Online, Description, Chemistry, Ingredients, Blackbox - Meropenem - RxList Monographs
		I.V. (meropenem for injection) and other antibacterial drugs, MERREM I.V. should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria.
		I.V. (meropenem for injection) is a sterile, pyrogen-free, synthetic, broad spectrum, carbapenem antibiotic for intravenous administration.
		Meropenem is soluble in 5% monobasic potassium phosphate solution, sparingly soluble in water, very slightly soluble in hydrated ethanol, and practically insoluble in acetone or ether.
	www.rxlist.com /cgi/generic/meropen.htm (245 words)

	meropenem - Hartford, Connecticut
		Meropenem is used in the treatment of infections of the abdomen, such as appendicitis and peritonitis, bacterial meningitis (infection of the lining of the brain), and skin infections.
		Meropenem is in the FDA pregnancy category B. This means that it is not expected to be harmful to an unborn baby.
		Meropenem will be administered as an intravenous (into a vein) injection by a healthcare provider.
	www.saintfranciscare.com /19175.cfm (787 words)

	Meropenem versus ceftazidime as empirical monotherapy in febrile neutropenia of paediatric patients with cancer -- ...
		Meropenem versus ceftazidime as empirical monotherapy in febrile neutropenia of paediatric patients with cancer -- Fleischhack et al.
		susceptibility of all viridans streptococcus strains to meropenem
		of meropenem and ceftazidime for this subgroup of infections
	jac.oxfordjournals.org /cgi/content/full/47/6/841 (5823 words)

	Drug Shortage Bulletin: Meropenem for Injection
		Meropenem injection is effective against susceptible strains of Streptococcus pneumoniae, Viridans group streptococci, Escherichia coli, Haemophilus influenzae, Klebsiella pneumoniae, Neisseria meningitidis, Pseudomonas aeruginosa, Bacteroides fragilis, Bacteroides thetaiotaomicron, and Peptostreptococcus species and is labeled for the treatment of intra-abdominal infections and bacterial meningitis caused by susceptible organisms.
		Meropenem (1.5 g/day) is as effective as imipenem/cilastatin (2 g/day) for the treatment of moderately severe intra-abdominal infections.
		Meropenem versus imipenem/cilastatin in the treatment of hospitalized patients with skin and soft tissue infections.
	www.ashp.org /shortage/drug.cfm?cfid=8854224&CFToken=96224054&id=1022 (688 words)

	Comparative In Vitro Killing Activities of Meropenem, Imipenem, Ceftriaxone, and Ceftriaxone plus Vancomycin at ...
		The penicillin, meropenem, imipenem, ceftriaxone, and vancomycin MICs are reported in Table 1.
		activity of meropenem was similar to that of ceftriaxone-vancomycin.
		Susceptibilities of 177 penicillin-susceptible and -resistant pneumococci to FK 037, cefpirome, cefepime, ceftriaxone, cefotaxime, ceftazidime, imipenem, biapenem, meropenem, and vancomycin.
	aac.asm.org /cgi/content/full/42/4/942 (1664 words)

	New Meropenem Dosing Strategy - UK Pharmacy Services (Site not responding. Last check: 2007-10-15)
		The traditional dosage regimen for meropenem for patients with normal renal function (creatinine clearance >50 ml/min) is 1 gram intravenously (IV) every 8 hours.
		Beta-lactams are time-dependent killers of bacteria and an optimal dosing regimen would maximize the time that the concentration of the antibiotic remains over the MIC of the organism.
		For patients with an estimated creatinine clearance of ≥ 50 ml/min, meropenem 500 mg IV every 6 hours is the approved dosing regimen.
	www.mc.uky.edu /pharmacy/dic/criteria/MeropenemUKdosing.htm (462 words)

	Meropenem Information on Healthline
		Meropenem is used in the treatment of infections of the abdomen, such as appendicitis and peritonitis, bacterial meningitis (infection of the lining of the brain), and skin infections.
		You may not be able to use meropenem, or you may require a dosage adjustment or special monitoring during treatment.
		Meropenem is in the FDA pregnancy category B. This means that it is not expected to be harmful to an unborn baby.
	www.healthline.com /multumcontent/meropenem (879 words)

	MedlinePlus Drug Information: Meropenem Injection
		The drug will be either injected into a large muscle (such as your buttock or hip) or added to an intravenous fluid that will drip through a needle or catheter placed in your vein for at least 15 minutes or more, one to three times a day.
		Meropenem eliminates bacteria that cause many kinds of infections, including pneumonia and urinary tract, skin, bone, and stomach infections.
		If you are receiving meropenem in your vein or under your skin, you need to know the symptoms of a catheter-related infection (an infection where the needle enters your vein or skin).
	www.nlm.nih.gov /medlineplus/druginfo/medmaster/a696038.html (698 words)

	Merrem™ (meropenem) Clinical Trial Summary - AstraZeneca Clinical Trials
		Merrem™ (meropenem) is an ultra-broad spectrum injectable antibiotic for a wide variety of serious infections, including meningitis and pneumonia.
		Meropenem versus ceftazidime as empirical monotherapy in febrile neutropenia of pediatric patients with cancer
		Observational, prospective, comparative study of the efficacy and tolerability of meropenem in the treatment of febrile episodes in neutropenic patients older than 64 years old (or younger than 65 years old but with renal insufficiency) with that of patients younger than 65 years old but with normal renal function.
	www.astrazenecaclinicaltrials.com /article/514083.aspx (418 words)

	MedlinePlus Medicinas: Inyección de Meropenem
		El meropenem elimina las bacterias que causan muchas clases de infecciones, incluyendo neumonía e infecciones a las vías urinarias, piel, huesos y al estómago.
		Su médico puede darle a usted un suministro para varios días de meropenem.
		Usted puede recibir una bolsa especial con el frasco de meropenem e instrucciones sobre cómo preparar la solución a administrar.
	www.nlm.nih.gov /medlineplus/spanish/druginfo/medmaster/a696038-es.html (766 words)

	New Meropenem Dosing Strategy - UK Pharmacy Services
		The traditional dosage regimen for meropenem for patients with normal renal function (creatinine clearance >50 ml/min) is 1 gram intravenously (IV) every 8 hours.
		Beta-lactams are time-dependent killers of bacteria and an optimal dosing regimen would maximize the time that the concentration of the antibiotic remains over the MIC of the organism.
		For patients with an estimated creatinine clearance of ≥ 50 ml/min, meropenem 500 mg IV every 6 hours is the approved dosing regimen.
	www.hosp.uky.edu /pharmacy/formulary/criteria/MeropenemUKdosing.htm (462 words)

	Meropenem (Systemic) - MayoClinic.com
		Meropenem (mer-oh-PEN-em) is used in the treatment of infections caused by bacteria.
		However, meropenem has not been reported to cause birth defects or other problems in animal studies.
		To help clear up your infection completely, meropenem must be given for the full time of treatment, even if you begin to feel better after a few days.
	www.mayoclinic.com /health/drug-information/DR203525 (1305 words)

	Meropenem (1.5 g/day) is as effective as imipenem/cilastatin (2 g/day) for the treatment of moderately severe ...
		Meropenem (1.5 g/day) is as effective as imipenem/cilastatin (2 g/day) for the treatment of moderately severe intra-abdominal infections.
		This multicentre, open-label, randomised trial compared meropenem (0.5 g/8 h) and imipenem/cilastatin (at the commonly used dosage of 0.5 g/6 h) in monotherapy in patients with moderately severe intra-abdominal infections (IAIs).
		At the end of therapy, 65/71 (91.6%) evaluable meropenem recipients were clinically cured or improved, compared to 60/64 (93.8%) imipenem/cilastatin recipients.
	www.tripdatabase.com /spider.html?itemid=243621 (692 words)

	European Society of Clinical Microbiology and Infectious Diseases
		The MICs of imipenem, meropenem, ceftazidime, piperacillin/tazobactam and ciprofloxacin were determined by agar dilution according to the BSAC guidelines.
		Meropenem had the lowest level of resistance at 1.9%, followed by piperacillin/tazobactam with 4.8%, imipenem at 5.8%, ceftazidime with 13.5% and ciprofloxacin with 20% resistance.
		At low MICs, meropenem was commonly more than 10-fold more active than imipenem, but as the imipenem MIC increased, the ratio decreased.
	www.blackwellpublishing.com /eccmid14/abstract.asp?id=14752 (274 words)

	Cystic Fibrosis \| A Support Community for those dealing with Cystic Fibrosis (Site not responding. Last check: 2007-10-15)
		Meropenem is an ultra-broad spectrum injectable antibiotic used to treat a wide variety of infections, including meningitis and pneumonia.
		Meropenem can be used interchangeably and is stable against kidney dihydropeptidase, therefore cilastin is not needed.
		Meropenem also has a reduced potential for causing seizures in comparison with imipenem.
	wiki.cysticfibrosis.com /index.php?title=Meropenem (114 words)

	Brief Communication: Tolerability of Meropenem in Patients with IgE-Mediated Hypersensitivity to Penicillins -- Romano ...
		Meropenem is an antibiotic that fights many of the same infections
		using meropenem in patients who are allergic to penicillin.
		Meropenem seems to be a treatment option for patients with penicillin
	www.annals.org /cgi/content/summary/146/4/266 (453 words)

	Laboratory Detection of Imipenem or Meropenem Resistance in Gram-negative Organisms \| CDC Infection Control in ... (Site not responding. Last check: 2007-10-15)
		Imipenem and meropenem are carbapenem antimicrobial agents used to treat a variety of serious infections when an organism is resistant to the primary agent of choice.
		Meropenem is slightly more active than imipenem against gram-negative organisms.
		Meropenem is a relatively new drug and more studies need to be published before susceptibilities of one carbapenem can be used to predict the other.
	www.cdc.gov /ncidod/dhqp/ar_lab_imipenem.html (736 words)

	Annals of Clinical Microbiology and Antimicrobials \| Full text \| Comparison in a rat thigh abscess model of imipenem, ...
		Antibiotic daily amounts and dosing were as follows: imipenem, 120 mg/kg every 8 h; meropenem 120 mg/kg every 8 h; cefoperazone 400 mg/kg/day (with a fixed ratio of [1:1] cefoperazone to sulbactam).
		Abscess from 17 rats in each the imipenem and cefoperazone-sulbactam groups and from 18 rats in the meropenem group were eligible.
		Results from two rats, one in the imipenem and one in the meropenem groups were excluded because of the technical problems during antibiotic bioassay test.
	www.ann-clinmicrob.com /content/3/1/2 (2154 words)

Try your search on: Qwika (all wikis)